MoonLake files FDA BLA for sonelokimab in hidradenitis
MoonLake submitted a BLA for sonelokimab to treat hidradenitis suppurativa, while reporting positive Phase 3 PsA results late in the quarter.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed